Selected References:
- Anderson KN, et al. 2020. ADHD medication use during pregnancy and risk for selected birth defects: national birth defects prevention study, 1998-2011. J Atten Disord, 24(3):479-489.
- Cohen JM, et al. 2017. Placental complications associated with psychostimulant use in pregnancy. Obstet Gynecol, 130(6):1192-1201.
- Golub M, et al. 2005. NTP CERHR expert panel report on the reproductive and developmental toxicity of amphetamine and methamphetamine. Birth Defects Res B Dev Reprod Toxicol, 74(6):471-584.
- Huybrechts KF, et al. 2018. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium. JAMA Psychiatry, 75(2):167-175.
- Ilett KF, et al. 2007. Transfer of dexamphetamine into breast milk during treatment for attention deficit hyperactivity disorder. Br J Clin Pharmacol, 63(3):371-375.
- Naeye RL, 1983. Maternal use of dextroamphetamine and growth of the fetus. Pharmacology, 26(2):117-120.
- Ornoy A, 2018. Pharmacological treatment of attention deficit hyperactivity disorder during pregnancy and lactation. Pharm Res, 35:46.
- Rose SJ, et al. 2020. Amphetamine–dextroamphetamine and pregnancy: neonatal outcomes after prenatal prescription mixed amphetamine exposure. Journal of Attention Disorders, 25(9):1295-1301.
- U.S. Food and Drug Administration. 2017. Vyvanse ® (lisdexamfetamine dimesylate). Retrieved September 2024 from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208510lbl.pdf.
